Shares of Moderna slid 3.01% to $152.52 on Friday, after two consecutive sessions in a row of gains.
Moderna’s last close was $157.26, 17.03% below its 52-week high of $178.50.
Moderna’s sales growth is 1428.1% for the ongoing quarter and 12348.6% for the next. The company’s growth estimates for the current quarter is a negative 48.6% and positive 528.6% for the next.
Year-on-year quarterly revenue growth grew by 826.4%, now sitting on 246.7M for the twelve trailing months.
Moderna’s Stock Top and Bottom Yearly Value
Moderna’s stock is valued at $152.52 on Friday, way below its 52-week high of $178.50 and way higher than its 52-week low of $17.68.
Moderna’s Moving Average
Moderna’s worth is way above its 50-day moving average of $88.87 and way higher than its 200-day moving average of $73.28.
Previous days news about Moderna
Moderna falls after Merck sells stake in the vaccine maker. According to Bloomberg Quint on Wed Dec 2, “Moderna Inc. fell in premarket trading in New York after Merck & Co. said it sold its stake in the biotechnology company that’s in the midst of developing a Covid-19 vaccine.”
Moderna expects to provide up to 125 mil covid-19 vaccine doses globally in q1. According to Business Insider on Fri Dec 4, “Moderna Inc. said Thursday that it expects to have between 100 million and 125 million doses of its potential COVID-19 vaccine available globally in the first quarter of 2021, with 85 million-100 million of those available in the U.S. And 15 million-25 million of those available outside of the U.S.”
Moderna to provide Israel health ministry with additional 4 million doses of its covid-19 vaccine candidate. According to MarketWatch on Fri Dec 4, “Moderna Inc. said Friday it is amending its supply agreement with the Israeli health ministry and will provide an additional 4 million doses of its experimental COVID-19 vaccine mRNA-1273. The amendment brings the total number of doses secured by Israel to 6 million.”